The study shows a loss of activating transcription factor 4 (ATF4), which is a downstream effector of pancreatic EIF2-α kinase (PERK) and a key regulator of the cellular stress response in BTZ resistance of osteosarcoma [98]. The gene discussed is ATF4; the disease is osteosarcoma.